Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Name: Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Published: 2026
License: Public Domain

Third Affiliated Hospital, Sun Yat-Sen University · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

adebrelimab (shr-1316), bevacizumab, hepatocellular carcinoma (hcc), interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Related documents